The link you have selected will take you to a site outside xeneticbio.com.

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

Xenetic Biosciences, Inc.

menu
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
  • Technology
    • DNase I Oncology Platform
    • Publications
  • Pipeline
    • Overview
    • XBIO-015
    • XBIO-020
  • News & Media
    • Press Releases
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference

Feb 11, 2020

Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

Jan 14, 2020

Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 15, 2019

Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

Oct 29, 2019

Xenetic Biosciences, Inc. to Present at BIO Investor Forum

Oct 16, 2019

Xenetic Biosciences, Inc. Provides Business Outlook

Oct 8, 2019

Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 15, 2019

Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform

Jul 22, 2019

Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering

Jul 17, 2019

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

Jun 24, 2019
  • « Previous
  • 1...
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • ...17
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2025Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap